Literature DB >> 17229741

Steroid-responsive leucoencephalopathy due to cholesterol embolism.

Patrice Laloux.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17229741      PMCID: PMC2077677          DOI: 10.1136/jnnp.2006.105981

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  5 in total

1.  Reversible encephalopathy associated with cholesterol embolism syndrome: magnetic resonance imaging and pathological findings.

Authors:  F Andreux; B Marro; N El Khoury; D Seilhean; S Alamowitch
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02       Impact factor: 10.154

2.  Clinical characteristics of pathologically proved cholesterol emboli to the brain.

Authors:  M A Ezzeddine; J M Primavera; J Rosand; E T Hedley-Whyte; G Rordorf
Journal:  Neurology       Date:  2000-04-25       Impact factor: 9.910

3.  Lacunar infarctions due to cholesterol emboli.

Authors:  P Laloux; J M Brucher
Journal:  Stroke       Date:  1991-11       Impact factor: 7.914

4.  Rupture of the arterial wall in two cases of recent cerebral embolism: morphological expression of cerebral vasospasm?

Authors:  J M Brucher; Y D De Smet; R E Gonsette
Journal:  J Neurol       Date:  1986-10       Impact factor: 4.849

5.  Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke.

Authors:  Pierre Amarenco; A Cohen; M Hommel; T Moulin; D Leys; M-G Bousser
Journal:  N Engl J Med       Date:  1996-05-09       Impact factor: 91.245

  5 in total
  2 in total

1.  Case of steroid-responsive encephalopathy from hypoglycaemia.

Authors:  Jay L Mathur; Fereshteh Rajabi; Allison Schroeder; Torben K Becker
Journal:  BMJ Case Rep       Date:  2017-08-24

Review 2.  Application of Plasma Exchange in Steroid-Responsive Encephalopathy.

Authors:  Yuting Jiang; Xin Tian; Yixue Gu; Feng Li; Xuefeng Wang
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.